Company: BSX
Filing Date: 2025-02-18
Form Type: 10-K
Source: 0000885725-25-000011
Chunk: 189

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-18
Form: 10-K
Item: Item 8
Chunk 189
---
,375 Research and development expenses427 7.9 %855 9.8 %1,282 Other segment items(1)20 0.4 %23 0.3 %43 Segment operating income(2)1,834 34.1 %2,281 26.2 %4,115 Unallocated amounts:Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(377)Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs(567)Amortization expense(828)Operating income (loss) 2,343 Other income (expense), net(358)Income (loss) before income taxes$1,985 

115

Year Ended December 31, 2022MedSurg% of net salesCardiovascular% of net salesTotalNet sales of reportable segments$4,855 $7,679 $12,535 Other(3)(60)Impact of foreign currency fluctuations208 Total net sales12,682 Segment expenses:Cost of products sold1,401 28.9 %2,637 34.3 %4,038 Selling, general and administrative expenses1,510 31.1 %2,454 32.0 %3,965 Research and development expenses432 8.9 %782 10.2 %1,214 Other segment items(1)23 0.5 %22 0.3 %45 Segment operating income(2)1,489 30.7 %1,784 23.2 %3,272 Unallocated amounts:Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments29 Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs(789)Amortization expense(803)Other(3)(60)Operating income (loss) 1,649 Other income (expense), net(508)Income (loss) before income taxes$1,141 (1) Includes royalty expense.(2) Calculated as